Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren Exploration of Digestive Diseases.2026;[Epub] CrossRef
Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu Frontiers in Nutrition.2025;[Epub] CrossRef
Beyond the liver: targeting the hepatic microenvironment and multi-organ networks for innovative MASH therapy Rong Fu, Fuyuan Zhang, Jingran Fu, Yuqian Li, Xuanzhe Zhu, Qian Ding, Yi-Zhun Zhu Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean? Eugene Han, Yong-ho Lee Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef
Association of HBV serological markers with host antiviral immune response relevant hepatic inflammatory damage in chronic HBV infection Bei Jiang, Leijie Wang, Huan Liu, Lin Wang, Rui Su, Liang Xu, Guochao Wei, Jia Li, Fengmin Lu, Xiangmei Chen Journal of Medical Virology.2024;[Epub] CrossRef
Although patients with cirrhosis are known to be in a state of “rebalance” in that pro- and anticoagulant factors increase the risk for both bleeding and thrombosis, the prevalence of portal vein thrombosis (PVT) in patients with cirrhosis can be up to 26%. Therefore, physicians should consider anticoagulation for the prevention and management of PVT in patients with cirrhosis who are at high risk of PVT. Vitamin K antagonist or low molecular weight heparin is suggested as the standard treatment for PVT in cirrhosis. With the advent of new direct-acting oral anticoagulants (DOACs), there is a paradigm shift of switching to DOACs for the treatment of PVT in patients with cirrhosis. However, the safety and efficacy of DOACs in the treatment of PVT was not well-known in patients with cirrhosis. Therefore, this review focused on the current knowledge about the efficacy, safety concerns, and hepatic metabolism of DOACs in patients with cirrhosis and PVT.
Citations
Citations to this article as recorded by
A glycoprotein UGP2A from the medicinal insect Ulomoides dermestoides alleviates deep vein thrombosis via the TLR4/MyD88 signaling pathway Qun Yu, Caiyi Wang, Yadan Dong, Mingrong Li, Ting Yan, Heng Liu, Chenggui Zhang, Jiapeng Wang, Huai Xiao International Journal of Biological Macromolecules.2026; 341: 150216. CrossRef
Sequential anticoagulation with LMWH and DOACs in cirrhotic portal vein thrombosis Melis Onay, Myriam Heilani, Chaarvee Gulia, Christoph Matthias, Eva Herrmann, Vitali Koch, Leon David Grünewald, Albrecht Piiper, Stefan Zeuzem, Mate Knabe Clinics and Research in Hepatology and Gastroenterology.2026; 50(4): 102792. CrossRef
Analysis of 6-week mortality and influencing factors in patients with liver cirrhosis and portal vein thrombosis complicated by acute gastrointestinal bleeding Junli Zhang, Ling Feng, Chih-Wei Tseng PLOS One.2026; 21(3): e0345079. CrossRef
Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival Madhumita Premkumar, Harish Bhujade, Prerna Sharma, Jasvinder Nain, Jasmina Ahluwalia, Anchal Sandhu, Yogendra Kumar, Sahaj Rathi, Sunil Taneja, Ajay Kumar Duseja, Anand V. Kulkarni, Charanpreet Singh, Shano Naseem, Tanka Karki, Pankaj Gupta, Sreedhara B. Alimentary Pharmacology & Therapeutics.2025; 61(6): 971. CrossRef
Comprehensive approach to liver cirrhosis treatment: Integrating ayurveda, homeopathy, and allopathy Debabrata Dash, Palak Kesharwani, Raj Kumar Koiri Pharmacological Research - Natural Products.2025; 6: 100184. CrossRef
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis Seema Sharma, Nishant Tiwari, Sampat Singh Tanwar Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(9): 11541. CrossRef
Machine learning models predict coagulopathy in traumatic brain injury patients in ER Haoyu Wang, Wenying Cao, Jianhuang Huang, Yuxing Feng, Cheng Li Frontiers in Neurology.2025;[Epub] CrossRef
Effect of Direct Oral Anticoagulants Versus Traditional Anticoagulation in Budd-Chiari Syndrome Xiaojuan Wu, Lijuan Liang, Jinghong Liu Clinical and Applied Thrombosis/Hemostasis.2025;[Epub] CrossRef
The relationship between gastroduodenal lesions and coronary heart disease N. U. Chamsutdinov, Ja. N. Abdulmanapova, N. A. Alieva, K. L. Seydalieva, A. R. Arbukhanova, M. A. Alakhverdieva, Z. M. Magomedova, R. G. Biybolatova Meditsinskiy sovet = Medical Council.2025; (15): 58. CrossRef
Comparative Effectiveness and Safety of Various Anticoagulation Regimens for Portal Venous Thrombosis in Cirrhosis: A Systematic Review and Network Meta-Analysis Zain ul Abideen, Muhammad Hassan Waseem, Noor Ul Huda Ramzan, Hamna Raheel, Fariha Hasan, Pawan Kumar Thada, Prasun K. Jalal Clinical and Applied Thrombosis/Hemostasis.2025;[Epub] CrossRef
Analysis of Related Influencing Factors of Portal Vein Thrombosis After Hepatectomy ShiGuai Qi, Jie Tao, Xinhua Wu, Xu Feng, Guoying Feng, Zhengrong Shi Journal of Laparoendoscopic & Advanced Surgical Techniques.2024; 34(3): 246. CrossRef
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis Chunwei Cheng, Juan Hua, Liang Xiong Clinical and Applied Thrombosis/Hemostasis.2024;[Epub] CrossRef
Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review Xiulin Xiao, Wengen Zhu, Qixin Dai Clinical and Applied Thrombosis/Hemostasis.2024;[Epub] CrossRef
Portal Vein Variations, Clinical Correlation, and Embryological Explanation: A Review Article Gareema Tyagi, Roshan K Jha Cureus.2023;[Epub] CrossRef
THE SURGEON'S PERSPECTIVE ON PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS S.M. Vasyliuk, V.I. Hudyvok, І.R. Labiak, N.M. Pavliuk, V.M. Atamaniuk Art of Medicine.2023; : 152. CrossRef
Heparins for prevention and treatment of venous thromboembolism in cirrhosis: Research advances Zhe Li, Wen-Tao Xu, Xiang-Bo Xu, Xing-Shun Qi World Chinese Journal of Digestology.2022; 30(9): 381. CrossRef
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated? Xiaobing Wang, Liping Chen Hepatology International.2022; 16(5): 1248. CrossRef
Direct oral anticoagulants (DOACs): From the laboratory point of view Sandra Margetić, Sandra Šupraha Goreta, Ivana Ćelap, Marija Razum Acta Pharmaceutica.2022; 72(4): 459. CrossRef
First
Prev
